Transchem (500422)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Trades at ₹38 against book value of ₹68.39, offering a 44% discount to stated net assets.
• Price-to-book of 0.56 provides potential downside cushion if assets are real and liquid.
• Latest quarter still shows net profit of ₹1 Cr, indicating some income source despite zero sales.
• No obvious operating losses in the current quarter, so cash burn appears limited.

Concerns

• Sales are ₹0 Cr with -100% sales growth, meaning the core pharmaceutical business is absent.
• Profit growth is -61.87%, and the P/E of 77.14 is expensive for a company with shrinking earnings.
• Piotroski F-Score of 3/9 signals poor overall financial health.
• Zero dividend and no disclosed promoter holding create uncertainty about shareholder returns and governance.

AI Analysis

Let me start with what Transchem is not: a going pharma concern. In the latest quarter, sales are ₹0 Cr. A business with no revenue has no pricing power, no moat, no economic engine. The -100% sales growth and -61.87% profit decline confirm this is not a growth story. The market cap is ₹48 Cr, yet book value is ₹68.39 per share; on the surface, a price-to-book of 0.56 appears cheap. But value investing is about buying assets that produce future earnings, not just balance sheet numbers. With ROE of only 3.79% and ROCE of 9.11%, this equity is earning very little. The P/E of 77.14 is absurd for a company with shrinking profits; it simply reflects a tiny profit base, not healthy earnings power. The Piotroski F-Score of 3/9 also flags weak financial health. There is no dividend, so shareholders are not being paid to wait. The 52-week range, from ₹214.80 down to ₹38.45, tells me Mr. Market has soured on this story, and the zero-sales quarter suggests he may be right. As Graham would say, price is what you pay, value is what you get. Here, the book value provides a possible floor, but only if the assets are genuine, liquid, and honestly carried. Without sales, what is the company actually doing? The ₹1 Cr net profit in the latest quarter smells like interest or other income, not operating strength. This may be a cigar-butt asset play, but you must demand a margin of safety given the poor fundamentals. I would wait for clarity on asset quality and any plan to revive operations before acting.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer